Mechanism of leukemogenesis through MLL-AF4 and its regulatory factors
| Project/Area Number |
17H07379
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | National Cancer Center Japan |
|---|
Principal Investigator |
Okuda Hiroshi 国立研究開発法人国立がん研究センター, 研究所, 外来研究員 (10629215)
|
|---|
| Project Period (FY) |
2017-08-25 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 白血病 / 発がん / MLL / AF4 / 転写 / SL1 / AEP / MLL白血病 / 癌 |
|---|
| Outline of Final Research Achievements |
11q23 chromosomal translocation is found in 7% of leukemia patients and an oncogene, MLL-fusion, is expressed by the translocation. MLL chimera fuses with a component of the AF4 transcriptional co-activator complex and constitutively activates the downstream genes to immortalize hematopoietic progenitor cells. Here, we identified a RSBN1 complex that binds to the AF4 complex, and assists with MLL-AF4 mediated leukemogenesis.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究成果によってMLL-AF4複合体による細胞の白血病化メカニズムをより詳細に解明することができた。１１番染色体転座をもつ白血病は難治であり、既存の治療法でも再発する例が多い。本研究成果を基にMLL-AF4複合体の機能を阻害する薬剤の開発ができれば、１１番染色体転座をもつ白血病を治療できるかもしれない。
|
Report
(3 results)
Research Products
(2 results)
